How to Renew Ocrevus (Ocrelizumab) Coverage with Aetna CVS Health in Virginia: Timeline, Forms & Bridge Options
Answer Box: Renewing Ocrevus Coverage with Aetna CVS Health in Virginia
To renew Ocrevus (ocrelizumab) with Aetna CVS Health in Virginia, submit your renewal request at least 2 weeks before your next scheduled infusion. You'll need updated clinical documentation showing disease stability or improvement, neurologist attestation, and confirmation that you're not using other MS disease-modifying therapies concurrently. Submit through Aetna's Availity portal or fax the completed precertification form to 1-888-267-3277. If denied, Virginia offers external review through the State Corporation Commission within 120 days.
Start today: Contact your neurologist's office to begin gathering renewal documentation and schedule any needed MRI or lab updates.
Table of Contents
- Renewal Triggers: When to Start the Process
- Evidence Update: What Documentation You Need
- Renewal Packet: Must-Include Documents
- Timeline: Submission and Decision Windows
- If Coverage Lapses: Bridge Options
- Annual Changes: What to Re-Verify
- Personal Tracker: Log Your Progress
- Common Renewal Challenges
- Virginia Appeals Process
- FAQ
Renewal Triggers: When to Start the Process
Don't wait until your last infusion to think about renewal. Aetna CVS Health requires prior authorization for Ocrevus continuation, and processing takes time.
Start your renewal process when:
- You're 6-8 weeks before your next scheduled infusion
- Your neurologist recommends continuing Ocrevus therapy
- You've completed at least one full treatment cycle (initial two infusions plus first maintenance dose)
- Your insurance plan year is approaching renewal
Tip: Set a calendar reminder 8 weeks before each scheduled infusion to begin renewal paperwork.
Signs you should start early:
- Previous renewal took longer than expected
- You've had recent hospitalizations or ER visits
- Your MRI shows new activity requiring documentation
- You're switching from another MS therapy to continue Ocrevus
Evidence Update: What Documentation You Need
Aetna's clinical policy for Ocrevus requires specific evidence of ongoing benefit and safety monitoring.
Treatment Response Documentation
Your neurologist must document:
- Disease stability or improvement while on Ocrevus
- Reduction in relapse frequency compared to pre-treatment
- Stable or improved disability scores (EDSS if available)
- MRI evidence of reduced disease activity
Required Clinical Updates
Diagnosis confirmation: Your MS diagnosis must remain eligible (relapsing forms, clinically isolated syndrome, or primary progressive MS).
Monitoring results:
- Recent MRI findings (typically within 12 months)
- Hepatitis B screening status if applicable
- Any infections or safety concerns since last approval
- Current neurological exam findings
Adherence documentation: Evidence that you've received infusions as scheduled and tolerated them well.
Clinician Corner: The medical necessity letter should specifically address disease stability, absence of concerning safety signals, and continued appropriateness of Ocrevus over alternative therapies.
Renewal Packet: Must-Include Documents
Core Requirements
- Completed Aetna Ocrevus Precertification Form
- Updated clinical notes from your neurologist
- Recent MRI report (within 12 months preferred)
- Treatment history including dates of previous infusions
- Current medication list confirming no concurrent MS DMTs
Additional Documentation
For initial renewals: Include baseline MRI and treatment response summary.
For ongoing renewals: Focus on stability metrics and any changes since last approval.
If you've had complications: Document how issues were managed and resolved.
Letter of Medical Necessity Structure
Your neurologist's letter should include:
- MS phenotype and diagnosis date with ICD-10 code
- Previous DMT trials and outcomes (if applicable)
- Current clinical status and EDSS score
- MRI findings supporting continued treatment
- Treatment goals and monitoring plan
- Attestation that no other MS DMTs are being used
Counterforce Health specializes in helping patients navigate complex prior authorization requirements like these. Their platform can help ensure your renewal documentation addresses all of Aetna's specific criteria and includes the right clinical evidence to support continued coverage.
Timeline: Submission and Decision Windows
Optimal Submission Timeline
| Timeframe | Action Required |
|---|---|
| 8 weeks before | Schedule neurologist appointment for renewal evaluation |
| 6 weeks before | Complete MRI if needed; gather documentation |
| 4 weeks before | Submit complete renewal packet to Aetna |
| 2 weeks before | Follow up on pending decisions; prepare for potential delays |
| 1 week before | Confirm approval or initiate expedited review if needed |
Aetna Processing Times
Standard processing: 5-10 business days for complete submissions Incomplete submissions: Additional 5-7 days after receiving missing information Expedited review: 72 hours for urgent medical situations
Submission Methods
- Availity portal (fastest option for providers)
- Fax: 1-888-267-3277 (verify current number)
- Electronic medical record integration where available
Contact for status updates:
- Aetna Precertification: 1-866-752-7021
- Commercial Plans: 1-888-632-3862
If Coverage Lapses: Bridge Options
If your Ocrevus renewal is delayed or denied, discuss these options with your neurologist:
Immediate Steps
- File an expedited appeal if medically urgent
- Request peer-to-peer review with Aetna's medical director
- Contact CVS Specialty about temporary supply options
- Explore manufacturer assistance programs
Bridge Therapy Considerations
Short-term corticosteroids: May help manage acute relapses but aren't a substitute for disease-modifying therapy.
Treatment timing flexibility: Ocrevus can be administered up to 6 weeks late without significantly compromising efficacy, giving you time for appeals.
Alternative infusion scheduling: Some patients may be able to receive treatment at hospital outpatient departments under different coverage rules.
Note: Never stop or delay Ocrevus without consulting your neurologist. Sudden discontinuation can lead to disease rebound in some patients.
Annual Changes: What to Re-Verify
Formulary Updates
Each January, check if Aetna has made changes to:
- Ocrevus formulary status or tier placement
- Prior authorization requirements
- Step therapy protocols
- Preferred site-of-care requirements
Plan Design Changes
Review your specific plan's:
- Specialty drug copay structure
- Annual deductible requirements
- Out-of-network coverage for infusion centers
- Appeals process updates
Documentation Requirements
Aetna may update their clinical criteria annually. Verify:
- New monitoring requirements
- Updated MRI frequency expectations
- Changes to concomitant medication restrictions
Personal Tracker: Log Your Progress
Renewal Checklist
8 Weeks Before Next Infusion:
- Schedule neurologist appointment
- Request MRI if needed
- Review current insurance benefits
6 Weeks Before:
- Obtain updated clinical notes
- Collect MRI reports
- Complete precertification form
4 Weeks Before:
- Submit complete renewal packet
- Confirm receipt with Aetna
- Schedule follow-up call
2 Weeks Before:
- Check approval status
- Prepare appeal if needed
- Confirm infusion appointment
Key Information to Track
- Current approval end date: ___________
- Next infusion scheduled: ___________
- Renewal submission date: ___________
- Aetna confirmation number: ___________
- Neurologist contact: ___________
- Infusion center: ___________
Common Renewal Challenges
Denial Reasons and Solutions
| Common Denial | How to Address |
|---|---|
| Lack of disease activity documentation | Submit recent MRI showing lesions or clinical relapses |
| Missing neurologist attestation | Ensure specialist signs and dates all forms |
| Concurrent DMT use concern | Provide complete medication list showing only Ocrevus |
| Insufficient treatment response | Document stability as clinical benefit; include EDSS scores |
Documentation Gaps
Missing MRI: Schedule urgent imaging if renewal is pending and recent MRI unavailable.
Incomplete clinical notes: Request detailed neurology visit summary addressing all Aetna criteria.
Timing issues: Submit renewal early to avoid coverage gaps during holiday or vacation periods.
Virginia Appeals Process
If Aetna denies your Ocrevus renewal, Virginia law provides strong patient protections through the State Corporation Commission's Bureau of Insurance.
Internal Appeals with Aetna
Timeline: 180 days from denial to file internal appeal Process: Submit written appeal with additional clinical documentation Decision time: 30-45 days for standard appeals; 72 hours for expedited
External Review in Virginia
After exhausting internal appeals, you can request external review:
Deadline: 120 days from final internal denial Forms: Form 216-A (External Review Request) Timeline: 45 days for standard review; 72 hours for expedited Cost: Free to patients
Submit to: State Corporation Commission Bureau of Insurance – External Review P.O. Box 1157 Richmond, VA 23218 Email: [email protected] Fax: (804) 371-9915
Virginia's external review process is binding on insurers and has successfully overturned many specialty drug denials when proper clinical evidence is presented.
When to Contact Virginia Regulators
- Aetna fails to respond within required timeframes
- You believe the denial violates Virginia insurance law
- Pattern of inappropriate denials for your condition
Virginia Bureau of Insurance Consumer Services: 1-877-310-6560
Platforms like Counterforce Health can be particularly valuable during the appeals process, helping ensure your documentation addresses Virginia's specific external review standards and includes all necessary clinical evidence.
FAQ
How long does Aetna CVS Health prior authorization take for Ocrevus renewal in Virginia? Standard processing is 5-10 business days for complete submissions. Submit at least 2 weeks before your scheduled infusion to avoid delays.
What if my MRI shows new lesions during renewal? New lesions may actually support continued Ocrevus coverage by demonstrating ongoing disease activity that requires treatment. Ensure your neurologist explains the clinical significance.
Can I switch infusion centers during renewal? Yes, but verify the new center is in-network with Aetna and can provide the required prior authorization documentation.
What happens if I miss my renewal deadline? Contact Aetna immediately to request expedited processing. You may need to file an appeal or external review if coverage has already lapsed.
Does step therapy apply to Ocrevus renewals? Generally not if you're already established on Ocrevus and showing clinical benefit. New step therapy requirements would typically apply only to new starts.
How often do I need MRI for renewal? Most policies expect MRI within 12 months of renewal, but frequency may vary based on your clinical stability and neurologist's recommendations.
What if Aetna changes their Ocrevus policy mid-year? Existing patients typically receive 30 days' notice of coverage changes and may be grandfathered under previous criteria for the remainder of the plan year.
Can I appeal if my renewal is approved but at a higher cost-share? Yes, formulary tier changes can be appealed if you can demonstrate medical necessity for the specific brand or if generic alternatives aren't appropriate.
Sources & Further Reading
- Aetna Ocrevus Precertification Form
- Aetna Clinical Policy: Multiple Sclerosis Agents
- Virginia External Review Process
- Virginia Bureau of Insurance Consumer Services
- Ocrevus Prescribing Information
Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on your specific insurance plan and clinical circumstances. Always consult with your healthcare provider and insurance company for personalized guidance. For assistance with complex prior authorization requirements, consider consulting with coverage advocacy services.
Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.